Athyrium Capital Management completed the acquisition of a minority stake in uMotif for £20m.

Athyrium Capital Management, an asset management company, completed the acquisition of a minority stake in uMotif, a data capture platform, for £20m. “We are delighted to welcome Athyrium to support our journey to be the most patient-centric platform for research. I truly believe that clinical research must put patients first, delivering more engaging research studies. With this investment from Athyrium I’m excited to grow our global capabilities to better serve our sponsors, partners and – most importantly – the patients we help take part in research,” Steve Rosenberg, uMotif CEO.